目的：腎病佔台灣十大死因之第七位，末期腎病是慢性不可逆的疾病，台灣每年有超過90%以上之病人，選擇以血液透析為維持生命之方法。目前無文獻報告磷酸二酯酵素抑制劑cilostazol 對血液透析的尿毒症病患的洗腎管預後的影響。研究方法：本研究樣本取自北部某醫學中心之透析患者，共101 名；研究工具採用「生活品質之健康量表SF-36」，問卷內容包括「病患基本資料」及「自覺健康量表」兩部分。結果：本研究在SF-36 健康量表八大構面中，服用Cilostazole™ 身體疼痛的平均得分為最高53.83 分(SD= 22.97)，因生理功能導致角色受限平均得分最低15.54 分(SD= 29.67)。患者對於身體生理功能上費力活動受很多限制，不費力的活動則不受限制，在生理健康問題、情緒功能問題均表示角色會受限制，自覺目前健康狀況方面較無活力，大部份患者有輕微的身體疼痛，在心理健康上覺得悶悶不樂和憂鬱，但不會因身體健康或情緒問題而妨礙到與家人或朋友的平常活動。使用AV-Shunt 洗腎病患之SF-36 構面分數，追蹤3 個月後，有無服用Cilostazole™ 藥物的病患其SF-36 構面分數無顯著差異。追蹤6 個月後，無服用Cilostazole™ 藥物的病患其「身體疼痛(BP)」與「一般健康(GH)」構面分數，顯著高於有服用Cilostazole™ 藥物的病患(p < 0.05)。追蹤12 個月後，無服用Cilostazole™ 藥物的病患其「心理健康(MH)」構面分數，顯著高於有服用Cilostazole™ 藥物的病患(p < 0.05)。但對於兩組之存活率則無顯著差異(log rank test =1.826, p = 0.18)。結論：本研究顯示，磷酸二酯酵素抑制劑cilostazol 對血液透析的尿毒症病患之存活率無顯著差異，但對其生活品質有影響。

Background and purpose: This paper examined factors affecting the quality of life of dialysis patients and evaluated their short- and long-term survival with an arteriovenous (AV) shunt and cilostazol. Methods: Subjects were hemodialysis patients with uremia in a medical center in northern Taiwan; 101 patients who had received an AV shunt implantation during 1 year were evaluated. The tool was the short form 36 health survey. Results: The results indicated that among 8 dimensions, the average score for bodily pain (BP) was highest at 53.83 (SD = 22.97) and that of role limitations due to physical problems (RP) was lowest at 15.54 (SD = 29.67). Since the labor-consuming activities of patients were limited but non-labor-consuming activities were less limited, they expressed that the role relating to physical health problems and emotional issues was limited, and theywere aware of less vitality concerning their health.Most patients had slight body pains and felt unhappy and bluementally. Nevertheless, they did not hinder the common activities of family members and friends due to their physical problems or emotional issues. Conclusions: According to the results, we suggest payingmore attention to the quality of life of dialysis patients, and future studies can carry out interventions to improve the quality of life of these patients. Cilostazol tended to increase the survival rate of patients with an AV shunt.